20 May 2013
Keywords: dr, reddy, net, profits, increase, fiscal, following
Article | 31 May 2001
Following the firm's decision to license out its antidiabetes agent DRF4158 to Novartis in a deal potentially worth $55 million (see ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
31 May 2001
30 May 2001
17 May 2013
© 2013 thepharmaletter.com